Current status of tuberculosis prevention and control in China and the legislative countermeasures

doi:10.19982/j.issn.1000-6621.20220529

Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (3): 244-247.doi: 10.19982/j.issn.1000-6621.20220529

• Legal Column • Previous Articles Next Articles

Current status of tuberculosis prevention and control in China and the legislative countermeasures

Cao Yanlin¹, Jiang Shiwen², Jia Fei¹, Zhang Ke¹, Chen Mingting²(), Chen Wei², Li Xue², Yang Jian³, Zhang Yi⁴

¹Department of Medical and Health Law, Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100020, China
²National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
³School of Public Health, Peking University, Beijing 100871, China
⁴Vanke School of Public Health, Tsinghua University, Beijing 100084, China

Received:2023-01-13 Online:2023-03-10 Published:2023-03-07
Contact: Chen Mingting E-mail:chenmt@chinacdc.cn
Supported by:
Bill & Melinda Gates Foundation’s Advocacy Project for the Prevention and Control of Major Infectious Diseases in the New Era(INV-035022);National Social Science Foundation Academic Group Project-Research on Key Legal Issues in the Implementation of the Basic Medical Care and Health Promotion Law(21STA052)

Abstract

Abstract:

Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis. At present, the tuberculosis epidemic is still relatively serious in China, and there is a big gap between China’s status and the global target set by World Health Organization to end tuberculosis. In the new situation that rule by law has become basic strategy of governance in China, there is no special legislation on tuberculosis prevention and control at the national level. The existing legal policies have problems such as low legal rank, early legislative time and lagging legislative content. Based on the international and domestic experience, the author believes that it is necessary to promote the legalization of tuberculosis prevention and control. It also puts forward some suggestions on the key points that need to be solved by legislation in tuberculosis prevention and control and how to promote legislation.

Key words: Tuberculosis, Communicable disease control, Legislation as topic

CLC Number:

Cao Yanlin, Jiang Shiwen, Jia Fei, Zhang Ke, Chen Mingting, Chen Wei, Li Xue, Yang Jian, Zhang Yi. Current status of tuberculosis prevention and control in China and the legislative countermeasures[J]. Chinese Journal of Antituberculosis, 2023, 45(3): 244-247. doi: 10.19982/j.issn.1000-6621.20220529

References 7

[1]	宋文虎. 卫生部决定将肺结核病从丙类传染病调整为乙类. 结核病健康教育, 1996(1):2.
[2]	World Health Organization.Global Tuberculosis Report 2022. Geneva: World Health Organization, 2022.
[3]	周琳, 刘磊. “三区三州”健康促进科普丛书:结核病. 北京: 人民卫生出版社, 2019.
[4]	成君, 夏愔愔, 刘二勇, 等. 学校结核病突发疫情处置的思考. 中国防痨杂志, 2018, 40(2): 145-148. doi:10.3969/j.issn.1000-6621.2018.02.006. doi: 10.3969/j.issn.1000-6621.2018.02.006
[5]	王前, 王黎霞, 李仁忠, 等. 三城市肺结核患者医疗费用及经济负担分析. 中国防痨杂志, 2013, 35(4): 240-245.
[6]	刘艳, 徐彩红, 王振宇, 等. 我国结核病定点医院肺结核患者家庭经济负担现况调查. 中华流行病学杂志, 2019, 40(5): 559-564. doi:10.3760/cma.j.issn.0254-6450.2019.05.013. doi: 10.3760/cma.j.issn.0254-6450.2019.05.013
[7]	杜世昌, 徐彩红, 王丽, 等. 新疆五县(区)肺结核患者医疗费用及经济负担现况的调查分析. 中国防痨杂志, 2018, 40(6): 609-615. doi:10.3969/j.issn.1000-6621.2018.06.012. doi: 10.3969/j.issn.1000-6621.2018.06.012

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.

Current status of tuberculosis prevention and control in China and the legislative countermeasures

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 7

Related Articles 15

Recommended Articles

Metrics

Comments